Rifampicin has - Compared to clindamycin - A dose and time dependent effect on hMSCs during osteogenic differentiation <i>in vitro</i>.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34305347.
- Also identified by DOI 10.1016/j.jor.2021.07.005 and PMC identifier 8283268.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effects of rifampicin and clindamycin on human mesenchymal stromal cell (hMSC) were examined. hMSC were cultured with rifampicin and clindamycin (0.5 μg/ml, 5 μg/ml, 50 μg/ml) and examinations of proliferation (Bromodeoxyuridine), calcification (Alizarin red) and mineralization (alkaline phosphatase) were performed after 7th, 14th and 21st days. With rifampicin (50 μg/ml) cultured hMSC showed a significant negative effect during proliferation, mineralization (7, 14 and 21 days) and calcification (21 days). Clindamycin seems to have no effect. Rifampicin in a dosage of 50 μg/ml showed a negative impact on proliferation, mineralization and calcification of hMSC after 21 days.